Resistance to Mycobacterium tuberculosis is a reality worldwide, and
its diagnosis continues to be difficult and time consuming. To face this challenge,
the World Health Organization has recommended the use of rapid molecular tests. We
evaluated the routine use (once a week) of a line probe assay (Genotype
MTBDRplus) for early diagnosis of resistance and for assessment
of the main related risk factors over 2 years. A total of 170 samples were tested: 15
(8.8%) were resistant, and multidrug resistance was detected in 10 (5.9%). The
sensitivity profile took 3 weeks (2 weeks for culture and 1 week for rapid testing).
Previous treatment for tuberculosis and the persistence of positive acid-fast smears
after 4 months of supervised treatment were the major risk factors observed. The use
of molecular tests enabled early diagnosis of drug-resistant bacilli and led to
appropriate treatment of the disease. This information has the potential to interrupt
the transmission chain of resistant M. tuberculosis.
Effective treatment of tuberculosis (TB) remains a serious public health problem in many countries, including Brazil, especially when considering drug-resistant disease. Xpert MTB/RIF has been implemented in many countries to reduce the time to TB diagnosis and to rapidly detect rifampicin resistance. The study aimed to describe and evaluate Xpert MTB/RIF performance in diagnosing pulmonary TB and rifampicin resistance in a tertiary healthcare facility in Brazil.A cross-sectional study was performed, which included all isolates of confirmed pulmonary TB patients from 2015 to 2018. Both Xpert MTB/RIF and GenoType MTBDRplus assays were performed to detect rifampicin and isoniazid resistance. In addition, isolates with detected resistance to rifampicin and/or isoniazid were analysed by phenotypic testing using MGIT-960 SIRE kit and whole-genome sequencing (WGS) using Illumina MiSeq Sequencing System.2148 respiratory specimens tested with Xpert MTB/RIF were included: n=1556 sputum, n=348 bronchoalveolar lavage and n=244 gastric washing. The overall Xpert MTB/RIF sensitivity in sputum was 94% and the overall specificity was 98%. The negative predictive value in sputum of all the patients was 99% with a positive predictive value of 89%. The concordance between Xpert MTB/RIF and phenotypic susceptibility test was 94.1%, while its concordance with WGS was 78.9%.Xpert MTB/RIF is a rapid and accurate diagnostic strategy for pulmonary TB, which can contribute to improvement in TB control. However, detection of rifampicin resistance might be associated with false-positive results.
Molecular-typing can help in unraveling epidemiological scenarios and improvement
for disease control strategies. A literature review of
Mycobacterium
tuberculosis
transmission in Brazil through genotyping on 56
studies published from 1996-2019 was performed. The clustering rate for
mycobacterial interspersed repetitive units - variable tandem repeats
(MIRU-VNTR) of 1,613 isolates were: 73%, 33% and 28% based on 12, 15 and
24-loci, respectively; while for RFLP-IS
6110
were: 84% among
prison population in Rio de Janeiro, 69% among multidrug-resistant isolates in
Rio Grande do Sul, and 56.2% in general population in São Paulo. These findings
could improve tuberculosis (TB) surveillance and set up a solid basis to build a
database of
Mycobacterium
genomes.
Background:The rate of tuberculosis (TB) infection among the prison population (PP) in Brazil is 28 times higher than that in the general population, and prison environment favors the spread of TB.Objective: To describe TB transmission dynamics and drug resistance profiles in PP using whole-genome sequencing (WGS).Methods: This was a retrospective study of Mycobacterium tuberculosis cultivated from people incarcerated in 55 prisons between 2016 and 2019; only one isolate per prisoner was included. Information about movement from one prison to another was tracked. Clinical information was collected, and WGS was performed on isolates obtained at the time of TB diagnosis.Results: Among 134 prisoners included in the study, we detected 16 clusters with a total of 58 (43%) cases of M. tuberculosis. Clusters ranged from two to seven isolates with five or fewer single nucleotide polymorphism (SNP) differences, suggesting a recent transmission. Six (4.4%) isolates were resistant to at least one anti-TB drug. Two of these clustered together and showed resistance to rifampicin, isoniazid, and fluoroquinolones, with 100% concordance between WGS and phenotypic drug-susceptibility testing. Prisoners with clustered isolates had a high amount of movement between prisons (two to eight moves) during the study period.Conclusions: WGS demonstrated the recent transmission of TB within prisons in Brazil. The high movement among prisoners seems to be related to the transmission of the same M. tuberculosis strain within the prison system. Screening for TB before and after the movement of prisoners using rapid molecular tests could play a role in reducing transmission.
Introduction: Mozambique is one of three countries with high prevalence of tuberculosis (TB), TB/human immunodeficiency virus coinfection, and multidrug-resistant TB. We aimed to describe Mycobacterium tuberculosis spoligotypes circulating among drug resistant (DR) strains from Beira, Mozambique comparing them with genotypes in the country. Methods: We performed spoligotyping of 79 M. tuberculosis suspected of DR-TB compared all spoligotype patterns published on the international database and PubMed. Results: Both in Beira and Mozambique (n=578), the main clades were Latin-American-Mediterranean, East-African-Indian, Beijing and T, with no extensively DR TB cases. Conclusions: Beira and Mozambique share the same population genetic structure of M. tuberculosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.